0000890465-13-000019.txt : 20130917
0000890465-13-000019.hdr.sgml : 20130917
20130917171940
ACCESSION NUMBER: 0000890465-13-000019
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20130916
FILED AS OF DATE: 20130917
DATE AS OF CHANGE: 20130917
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BESHAR LUKE M
CENTRAL INDEX KEY: 0001192128
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 131102018
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
STREET 2: 3RD FLOOR
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2013-09-16
0000890465
NPS PHARMACEUTICALS INC
NPSP
0001192128
BESHAR LUKE M
550 HILLS DRIVE
BEDMINSTER
NJ
07921
0
1
0
0
EVP & CFO
Common Stcok
2013-09-16
4
M
0
50000
4.05
A
109180
D
Common Stock
2013-09-16
4
S
0
49900
27.89
D
59280
D
Common Stock
2013-09-16
4
S
0
100
28.65
D
59180
D
Stock Options
4.05
2013-09-16
4
M
0
50000
0
D
2017-11-20
Common Stock
50000
0
D
The shares were sold pursuant to a predefined price target in a trading plan qualified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, that was effective August 16, 2013.
The price shown above represents the weighted average price of the shares sold. The range of sales prices was $27.61 and $28.53. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC Staff, upon request, information regarding the number of shares sold at each price within the range of prices actually paid.
On November 20, 2007, the Reporting Person received a grant of 200,000 stock options under the Issuer's 1998 Stock Option Plan. The options become exercisable based on the following vesting schedule: 28% on the first anniversary of the grant and 2% each month thereafter. As of the date of this filing, all 200,000 stock options have vested.
/s/ Luke Beshar, by Edward Startemeier as attorney-in-fact
2013-09-17